Zopa Retreatment and Vector Shedding in Adults With RRP
Recruiting now · Phase 4
Conditions studied: Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae
In brief
This open-label study evaluates safety, vector shedding, and retreatment efficacy of Zopapogene imadenovec (Zopa) in adults with recurrent respiratory papillomatosis (RRP). Two cohorts will be enrolled (n=30): Cohort 1 to assess the magnitude and duration of adenoviral vector shedding in urine, feces, skin, and nasal tissue; Cohort 2 to assess the complete response rate following retreatment.
Key facts
- Study ID
- NCT06538480
- Run by
- Precigen, Inc
- People needed
- 30
- Starts
- 2024-07-11
- Expected to finish
- 2028-12-02
- Last updated by the study team
- 2025-12-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Winship Cancer Institute, Emory University — Atlanta, Georgia, United States (enrolling)
- National Institute of Health — Bethesda, Maryland, United States (enrolling)
- University of Cincinnati — Cincinnati, Ohio, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.